Instructions for Use Saphnelo® Pen [saf-NEL-oh]
(anifrolumab-fnia)
injection, for subcutaneous use
Single-dose Autoinjector
(anifrolumab-fnia)
injection, for subcutaneous use
Single-dose Autoinjector
Download a PDF version of the Instructions for Use for SAPHNELO PEN.
THANKS FOR REGISTERING!
THANKS FOR REGISTERING!
By completing this registration, I confirm that I am at least 18 years old, agree to receive information about SAPHNELO, and may receive information about other immunology medicines and services related to my condition which includes, but is not limited to, educational and promotional materials, special offers and services and for market research purposes, which includes contacting me to participate in focus groups, surveys or interviews. This may include AstraZeneca or a third party working on AstraZeneca's behalf contacting me by telephone, e-mail and text message regarding AstraZeneca Support Programs that may be of interest to me. Information provided by AstraZeneca does not take the place of talking to your healthcare provider about your treatment or condition. If you no longer want to receive health-related materials, call 1-800-236-9933. Please visit www.azprivacynotice.com to review our Privacy Notice.
By providing your phone number, you are opting in to receive updates and support messages from SAPHNELO. Text STOP to opt out. Text HELP for help. Message frequency will vary. Message and data rates may apply. For more information, visit Privacy Notice or Terms & Conditions.


Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. SAPHNELO may affect the way other medicines work, and other medicines may affect how SAPHNELO works.
SAPHNELO may cause serious side effects, including:
The most common side effects of SAPHNELO include:
These are not all the possible side effects of SAPHNELO. Call your healthcare provider for medical advice about side effects.
SAPHNELO is a prescription medicine used to treat adults with moderate to severe systemic lupus erythematosus (SLE or lupus) who are receiving other lupus medicines.
It is not known if SAPHNELO is effective in patients with severe active lupus nephritis or severe active central nervous system lupus. It is not known if SAPHNELO is safe and effective in patients under 18 years of age.
Please see full Prescribing Information, including Patient Information.
You may report side effects related to AstraZeneca productsOpens new window.